Enrasentan | SB-217242 | CAS#167256-08-8 | endothelin antagonist

MedKoo Cat#: 326696 | Name: Enrasentan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enrasentan, also known as SB-217242, is a dual receptor endothelin antagonist with a higher affinity for ET(A) receptors. In an animal model of hypertension and cardiac hypertrophy the drug has reduced blood pressure, prevented cardiac hypertrophy and preserved myocardial function. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Chemical Structure

Enrasentan

CAS#167256-08-8 (free base)

Theoretical Analysis

MedKoo Cat#: 326696

Name: Enrasentan

CAS#: 167256-08-8 (free base)

Chemical Formula: C29H30O8

Exact Mass: 506.1941

Molecular Weight: 506.55

Elemental Analysis: C, 68.76; H, 5.97; O, 25.27

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

167256-08-8 (free base) 183507-63-3 (edamine)

Synonym

SB-217242; SB 217242; SB217242; Enrasentan

IUPAC/Chemical Name

(1S,2R,3S)-3-(2-(2-Hydroxyethoxy)-4-methoxyphenyl)-1-(3,4-(methylenedioxy)phenyl)-5-propoxy-2-indancarboxylic acid

InChi Key

GLCKXJLCYIJMRB-UPRLRBBYSA-N

InChi Code

InChI=1S/C29H30O8/c1-3-11-34-19-6-7-20-22(14-19)27(21-8-5-18(33-2)15-24(21)35-12-10-30)28(29(31)32)26(20)17-4-9-23-25(13-17)37-16-36-23/h4-9,13-15,26-28,30H,3,10-12,16H2,1-2H3,(H,31,32)/t26-,27+,28+/m0/s1

SMILES Code

O=C([C@@H]1[C@@H](C2=CC(OCO3)=C3C=C2)C4=C(C=C(OCCC)C=C4)[C@H]1C5=CC=C(OC)C=C5OCCO)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 506.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Prasad SK, Dargie HJ, Smith GC, Barlow MM, Grothues F, Groenning BA, Cleland JG, Pennell DJ. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart. 2006 Jun;92(6):798-803. Epub 2005 Dec 9. PubMed PMID: 16339819; PubMed Central PMCID: PMC1860639. 2: Cosenzi A. Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16. Review. PubMed PMID: 12595914. 3: Cosenzi A, Bernobich E, Bonavita M, Bertola G, Trevisan R, Bellini G. Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia. J Cardiovasc Pharmacol. 2002 Apr;39(4):488-95. PubMed PMID: 11904522. 4: Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17. PubMed PMID: 11588531. 5: Brooks DP, DePalma PD. Unmasking of endothelin-1-induced natriuresis and renal vasodilation in the dog by enrasentan (SB 217242). J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S346-7. PubMed PMID: 11078416.